The levels of Gal‐9 in bone marrow supernatants, serum (n = 15, samples: 038‐052) and culture supernatants of MDSCs (n = 3, samples: 048, 049, 050) from both low‐risk and high‐risk MDS were significantly higher than those in NC (bone marrow supernatant: 323.6 ± 42.6 pg/mL vs 381 ± 55.98 pg/mL vs 154.9 ± 23.72 pg/mL, P = .0042**; serum: 194.5 ± 16.13 pg/mL vs 237.1 ± 7.18 pg/mL vs 69.81 ± 11.93 pg/mL, P < .0001****; culture supernatants of MDSCs: 147.7 ± 5.24 pg/mL vs 14.2 ± 0.55 pg/mL, P < .0001****) (Figure 1E), but there was no difference between the low‐risk and high‐risk groups. The gene discussed is LGALS9; the disease is myelodysplastic syndrome.